AFT Pharmaceuticals (NZX.AFT, ASX.AFP) announces its achievement of registration for sale of its long-lasting hand sanitiser Crystawash® Extend in China.
AFT also announces it has signed further new licence agreements for the intravenous dose form of its Maxigesic pain relief medicine as it continues to build momentum in its international business.
The Chinese National Medical Products Administration (NMPA) approved Crystawash Extend – 24-hour long-lasting hand sanitiser which allows AFT to sell into retail stores in mainland China. Crystawash Extend sanitises and protects against 99.99% of germs for up to 24 hours. It is non-toxic & alcohol-free. AFT will commercialise this product range within the next 6 to 12 months into mainland China.
The privately owned Swiss pharmaceutical company Labatec has licensed the intravenous form, Maxigesic IV®, in Switzerland. Labatec and AFT are aiming for registration and launch of the medicine – a treatment for mild to moderate pain for use post-operatively in hospitals when patients cannot take a medicine orally – in the next 12 to 18 months.
Pharma Bavaria has extended its existing Maxigesic IV license agreement in Latin America to include Argentina and Paraguay in addition to the licenses already agreed with AFT for the medicine in Bolivia, Chile, Columbia, Ecuador, Peru, and Uruguay.
The agreements build on launches of Maxigesic IV since the start of the year in the Netherlands, Denmark, Sweden, Norway, and Finland.
AFT Managing Director Dr Hartley Atkinson said: “These licensing, registration and distribution agreements and the recent launches will add to the growing momentum we are seeing in the company’s international business.
“As a result of these launches and recent sales AFT will enter the new financial year with Maxigesic sold in 61 countries in various dose forms, 15 more than where we were in March 2022, although just short of our target of 63 countries. We are pleased with the progress we are making in realising the potential of our Maxigesic intellectual property. Additionally, we are pleased to achieve our first product registration in Mainland China and further registrations are pending.”
For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial Officer.
For more information:
Media:
Richard Inder
The Project
Tel: +64 9488 0232
Investors:
Dr Hartley Atkinson
Managing Director
AFT Pharmaceuticals Tel: +64 21 645 643
